BACKGROUND: We evaluated the safety of nicotine replacement therapy (NRT) in active smokers with acute (aneurysmal) subarachnoid hemorrhage (SAH). METHODS: A retrospective observational cohort study was conducted in a prospectively collected database including all SAH patients admitted to an 18-bed neuro-ICU between January 1, 2001 and October 1, 2007. Univariate and multivariable models were constructed, employing stepwise logistic regression. The primary endpoint was 3-month mortality. Delayed cerebral ischemia (DCI) due to vasospasm, angiographic and TCD evidence of vasospasm, and delirium were secondary endpoints. RESULTS: Active cigarette smokers admitted with SAH included 128 that received NRT and 106 that did not. Patients were well-matched for age, admission Hunt-Hess Grade, radiographic findings, and APACHE II scores, but those who received NRT were more likely to be heavy smokers (>10 cigarettes daily), diabetic, heavy alcohol users, and to have cerebral edema on admission. NRT was associated in multivariate analysis with a lower risk of death at 3 months (OR 0.12, 95% CI 0.04-0.37, P < 0.001). There were no differences in the frequency of DCI and most other medical complications, but delirium (19 vs. 9%, P = 0.006) and seizures (9 vs. 2%, P = 0.024) were more common in patients who received NRT. CONCLUSIONS: Despite vasoactive properties, administration of NRT among active smokers with acute SAH appeared to be safe, with similar rates of vasospasm and DCI, and a slightly higher rate of seizures. The association of NRT with lower mortality could be due to chance, to uncontrolled factors, or to a neuroprotective effect of nicotine in active smokers hospitalized with SAH, and should be tested prospectively.
BACKGROUND: We evaluated the safety of nicotine replacement therapy (NRT) in active smokers with acute (aneurysmal) subarachnoid hemorrhage (SAH). METHODS: A retrospective observational cohort study was conducted in a prospectively collected database including all SAHpatients admitted to an 18-bed neuro-ICU between January 1, 2001 and October 1, 2007. Univariate and multivariable models were constructed, employing stepwise logistic regression. The primary endpoint was 3-month mortality. Delayed cerebral ischemia (DCI) due to vasospasm, angiographic and TCD evidence of vasospasm, and delirium were secondary endpoints. RESULTS: Active cigarette smokers admitted with SAH included 128 that received NRT and 106 that did not. Patients were well-matched for age, admission Hunt-Hess Grade, radiographic findings, and APACHE II scores, but those who received NRT were more likely to be heavy smokers (>10 cigarettes daily), diabetic, heavy alcohol users, and to have cerebral edema on admission. NRT was associated in multivariate analysis with a lower risk of death at 3 months (OR 0.12, 95% CI 0.04-0.37, P < 0.001). There were no differences in the frequency of DCI and most other medical complications, but delirium (19 vs. 9%, P = 0.006) and seizures (9 vs. 2%, P = 0.024) were more common in patients who received NRT. CONCLUSIONS: Despite vasoactive properties, administration of NRT among active smokers with acute SAH appeared to be safe, with similar rates of vasospasm and DCI, and a slightly higher rate of seizures. The association of NRT with lower mortality could be due to chance, to uncontrolled factors, or to a neuroprotective effect of nicotine in active smokers hospitalized with SAH, and should be tested prospectively.
Authors: Matthijs Kox; Astrid W Hoedemaekers; Peter Pickkers; Johannes G van der Hoeven; Jan C Pompe Journal: Crit Care Med Date: 2007-10 Impact factor: 7.598
Authors: A M Joseph; S M Norman; L H Ferry; A V Prochazka; E C Westman; B G Steele; S E Sherman; M Cleveland; D O Antonuccio; D O Antonnucio; N Hartman; P G McGovern Journal: N Engl J Med Date: 1996-12-12 Impact factor: 91.245
Authors: Jennifer Ballard; Kurt T Kreiter; Jan Claassen; Robert G Kowalski; E Sander Connolly; Stephan A Mayer Journal: Stroke Date: 2003-07-03 Impact factor: 7.914
Authors: Jan Claassen; An Vu; Kurt T Kreiter; Robert G Kowalski; Evelyn Y Du; Noeleen Ostapkovich; Brian-Fred M Fitzsimmons; E Sander Connolly; Stephan A Mayer Journal: Crit Care Med Date: 2004-03 Impact factor: 7.598
Authors: Katja E Wartenberg; J Michael Schmidt; Jan Claassen; Richard E Temes; Jennifer A Frontera; Noeleen Ostapkovich; Augusto Parra; E Sander Connolly; Stephan A Mayer Journal: Crit Care Med Date: 2006-03 Impact factor: 7.598
Authors: Ben de Jong; Anne Sophie Schuppers; Arriette Kruisdijk-Gerritsen; Maurits Erwin Leo Arbouw; Hubertus Laurentius Antonius van den Oever; Arthur R H van Zanten Journal: Ann Intensive Care Date: 2018-06-07 Impact factor: 6.925
Authors: Christian V Eisenring; Preci L Hamilton; Bawarjan Schatlo; David Nanchen; Philippe Herzog; Markus F Oertel; Isabelle Jacot-Sadowski; Felice Burn; Jacques Cornuz Journal: Adv Ther Date: 2022-09-19 Impact factor: 4.070